DMIIU NASDAQ
Drugs Made In America Acquisition II Corp. Unit
1W: +0.0%
1M: -0.1%
3M: +0.7%
YTD: +2.3%
1Y: +2.2%
$10.29
+0.06 (+0.59%)
After Hours: $9.09 (-1.20, -11.71%)
Credit Risk of going bust: not rated, financial company (lending is its business) Bonds: none of note held by US funds details ▾
Not rated: lending and leverage are a financial company's business, which the model misreads.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$648.8M
52W Range9.97-10.8
Volume0
Avg Volume411
Beta0.06
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORoger Bendelac
Employees2
SectorFinancial Services
IndustryShell Companies
IPO Date2025-09-25
Websitedmaacorp.com/
420 Lexington Avenue
New York, NY 10170
US
New York, NY 10170
US
954 870 3099
About Drugs Made In America Acquisition II Corp. Unit
DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business. The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing the United States' reliance on international drug manufacturing. Each investment unit comprises one common stock share and an associated right, which entitles the holder to an additional one-tenth of a share once a suitable business combination is successfully finalized.
Latest News
No recent news
Recent Insider Trades
No insider trades found